Pfizer Tikosyn Roll-Out Tied To Hospital And Physician Training Program
Executive Summary
Pfizer is developing a pilot training program in preparation for the launch of the anti-arrhythmic Tikosyn (dofetilide) in the first quarter of 2000.
You may also be interested in...
CERTs Risk Management Agenda Includes Tikosyn Study, Workshops
The initial results from a CERT study of the risk management program for Pfizer's anti-arrhythmia drug Tikosyn (dofetilide) may indicate some practical limits to well-designed monitoring plans, Office of Postmarketing Drug Risk Assessment Director Peter Honig, MD, suggested Nov. 5
CERTs Risk Management Agenda Includes Tikosyn Study, Workshops
The initial results from a CERT study of the risk management program for Pfizer's anti-arrhythmia drug Tikosyn (dofetilide) may indicate some practical limits to well-designed monitoring plans, Office of Postmarketing Drug Risk Assessment Director Peter Honig, MD, suggested Nov. 5
FDA To Study "Labeling Fatigue": Do Serial Changes Influence Prescribing?
FDA is planning an internal research effort to examine the concept of "labeling fatigue," which suggests that serial label changes or extensive warnings in the package insert have limited ability to alter prescribing behavior.